PrEP therapeutics protocol

There have been recent expansions in the number and nature of PrEP agents with further developments anticipated. Use of PrEP formulations should be dictated in line with the British Association of Sexual Health and HIV/British HIV Association PrEP guidance, in the following order, factoring in: 

• Clinical considerations (specifically renal and bone comorbidities) including risk/benefit assessment 

• Cost effectiveness 

• Patient adherence and attendance 

Download/print copy of the NHS Scotland PrEP therapeutics protocol